0000899243-21-047320.txt : 20211208 0000899243-21-047320.hdr.sgml : 20211208 20211208160927 ACCESSION NUMBER: 0000899243-21-047320 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20211206 FILED AS OF DATE: 20211208 DATE AS OF CHANGE: 20211208 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zarrabian Saiid CENTRAL INDEX KEY: 0001495521 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37823 FILM NUMBER: 211478754 MAIL ADDRESS: STREET 1: P.O. BOX 675765 CITY: RANCHO SANTA FE STATE: CA ZIP: 92067 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kintara Therapeutics, Inc. CENTRAL INDEX KEY: 0001498382 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 990360497 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 12707 HIGH BLUFF DR., SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 350-4364 MAIL ADDRESS: STREET 1: 12707 HIGH BLUFF DR., SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: DelMar Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20130123 FORMER COMPANY: FORMER CONFORMED NAME: Berry Only Inc. DATE OF NAME CHANGE: 20100805 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-12-06 0 0001498382 Kintara Therapeutics, Inc. KTRA 0001495521 Zarrabian Saiid 12707 HIGH BLUFF DR., SUITE 200 SAN DIEGO CA 92130 1 1 0 0 Head of Strategic Partnerships Common Stock 2021-12-06 4 P 0 11891 0.5902 A 17391 D Common Stock 2021-12-07 4 P 0 38109 0.6376 A 55500 D Common Stock 590 I By Child The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.59 to $0.5902 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. On May 8, 2019, Kintara Therapeutics, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The number of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.63115 to $0.6415 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Exhibit 24 - Power of Attorney /s/ Saiid Zarrabian 2021-12-08 EX-24 2 attachment1.htm EX-24 DOCUMENT

                               POWER OF ATTORNEY

       Known by all those present, that Saiid Zarrabian hereby constitutes
and appoints Scott Praill as his true and lawful attorney-in-fact with respect
to DelMar Pharmaceuticals, Inc. to:

      (1) prepare, execute in the undersigned's name and on the
      undersigned's behalf, and submit to the U.S. Securities and Exchange
      Commission (the "SEC") a Form ID, including amendments thereto, and any
      other documents necessary or appropriate to obtain codes and passwords
      enabling the undersigned to make electronic filings with the SEC of
      reports required by Section 13 and 16(a) of the Securities Exchange Act of
      1934, or any rule or regulation of the SEC;

      (2) execute for and on behalf of the undersigned Schedules 13D and
      13G, and Forms 3, 4 and 5 in accordance with Sections 13 and 16(a) of the
      Securities Exchange Act of 1934 and the rules thereunder;

      (3) do and perform any and all acts for and on behalf of the
      undersigned which may be necessary or desirable to complete and execute
      any such Schedules 13D or 13G, and Forms 3, 4, and 5, complete and execute
      any amendment or amendments thereto, and timely file such form with the
      SEC and any stock exchange or similar authority; and

      (4) take any other action of any type whatsoever in connection with
      the foregoing which, in the opinion of such attorney-in-fact, may be of
      benefit to, in the best interest of, or legally required by, the
      undersigned, including without limitation the execution and filing of a
      Form 4 with respect to a transaction which may be reported on a Form 5, it
      being understood that the documents executed by such attorney-in-fact on
      behalf of the undersigned pursuant to this Power of Attorney shall be in
      such form and shall contain such terms and conditions as such attorney-in-
      fact may approve in such attorney in fact's discretion.

      The undersigned hereby grants to attorney-in-fact full power and authority
to do and perform any and every act and thing whatsoever requisite, necessary,
or proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's designated substitute or substitutes, shall lawfully do or
cause to be done by virtue of this Power of Attorney and the rights and powers
herein granted. The undersigned acknowledges that the foregoing attorney-in-
fact, in serving in such capacity at the request of the undersigned, is not
assuming any of the undersigned's responsibilities to comply with Sections 13
and 16 of the Securities Exchange Act of 1934, as amended, and the rules
thereunder.

      This Power of Attorney shall remain in full force and effect until revoked
by the undersigned in a signed writing delivered to the foregoing
attorney-in-fact.

      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
 to be executed as of this 12 day of September, 2019.


                                    /s/ Saiid Zarrabian
                                    ----------------------
                                    Name: Saiid Zarrabian